Analyst Research

Report Title Price
Provider: ValuEngine, Inc.
$25.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: Ford Investor Services, Inc.
$12.00
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Regado Biosciences Inc announces private placement of common stock


Friday, 31 Jan 2014 08:15am EST 

Regado Biosciences Inc:Says it has entered into a definitive agreement to sell $20 mln of its common stock in a private placement to new and existing investors.Says under the agreement, the investors will purchase an aggregate of 4 mln shares of common stock at a purchase price of $5 per share.Says the net proceeds of the offering are expected to be used for general corporate and working capital purposes, including the ongoing Phase 3 REGULATE-PCI clinical trial.Says the company believes that the expected net proceeds of this offering, together with its existing working capital, will be sufficient to fund the REGULATE-PCI trial through the second interim analysis, which is expected to occur by the end of the third quarter of 2014.Says Cowen and company acted as the lead placement agent for the offering, and BMO Capital Markets acted as co-placement agent.Says the offering is expected to close on Feb. 5. 

Company Quote

1.02
-0.02 -1.92%
1:33pm EDT